Bioprocess analytics & PAT (process analytical technology)

01Overview and value chain#

Markers EC: ICH Q8/Q10 QbD & EU GMP Annex 11 | OECD: Bio-pharma | Regulator: FDA (USA), EMA (EU), NMPA (China)

Process analytical technology (PAT) instruments a bioprocess so quality is measured and controlled in real time rather than inferred from end-of-batch testing. In-line Raman, near-IR and UV probes feed multivariate models that predict critical quality attributes (CQAs), closing the loop between sensor and control. The payoff is concrete: continuous Raman feedback in upstream culture can raise monoclonal-antibody titer by around 10% and cut glycation by up to 60% versus intermittent sampling, while continuous chromatography downstream can reduce buffer use by about 40%. The same data backbone — chromatography, high-resolution mass spectrometry and chemometrics — underpins real-time release testing, which compresses batch disposition from days toward a single shift. PAT is encouraged, not mandated, by regulators as the operational core of Quality-by-Design.

Key directions of bioprocess analytics & PAT:

1. In-line Raman process analytics (Raman Process Analytics): single-use probes track glucose, lactate and titer in real time, enabling automated feedback control.
2. Continuous chromatography (Continuous Chromatography): multi-column periodic counter-current purification at steady state, cutting buffer use about 40% versus batch.
3. Process mass spectrometry and LC (Mass Spec & LC): high-resolution Orbitrap MS and UPLC for protein characterization and impurity profiling.
4. Process orchestration and MES/SCADA (Process Orchestration): multivariate analysis, digital twins and real-time release tying instruments into one control system.

Sectoral value chain#

[sampling] ──> [in-line sensing] ──> [CQA modeling] ──> [process control]
                                  │
                          (CQAs + feedback)
                                  │
                                  ▼
[real-time release] <─── [QC analytics] <─────┘

Value chain levels#

Cross-cutting technologies of the sector:

• Chemometrics and MVDA (Multivariate Data Analysis): statistical models turning spectra into attributes.
• Single-use sensor probes (Single-Use Probes): gamma-sterilizable in-line optical probes.
• AI quality prediction and digital twins (AI Quality Prediction): machine-learning models for feed-forward control.

02US#

The US anchors PAT regulation through the FDA’s PAT initiative and leads in high-resolution mass spectrometry and continuous chromatography.

fda pat initiative, high-res mass spec, continuous chromatography#

• Cytiva: the AKTA pcc continuous multi-column chromatography system runs true periodic counter-current purification, cutting buffer use by about 40% versus batch, with UNICORN dimensionless scaling from 1 to 100 mL/min and FDA 21 CFR Part 11 / ISO 13485 compliance.
• Waters Corporation: its BioResolve Peptide and GTxResolve Lipid columns (230 Å) deliver up to 3x faster GLP-1 characterization and 2x faster LNP analysis, with a global launch from June 2026.
• Thermo Fisher Scientific: the Orbitrap Tribrid Apex and Excedion mass spectrometers add enhanced dynamic range detecting 3–5x more compounds, paired with AI-enabled BioPharma Finder 5.5 (unveiled at ASMS 2026).

03CN#

China is localizing high-end bioprocess instrumentation, moving from lyophilizers and bioreactors into integrated PAT sensing.

domestic instrument scale-up, bioreactor PAT, pharma equipment#

• Tofflon (300171): a lyophilizer leader with roughly 60% of China’s mid-to-high-end market, now building 10–15,000 L stainless bioreactors with PAT sensors; it reported about 5.23 billion yuan of 2025 revenue and leads an MIIT high-performance-bioreactor project (30 IP filings, 5 patents).
• Truking (Chutian Technology): a pharma-equipment maker that posted about 5.76 billion yuan of 2025 revenue with net profit up 156% to roughly 255 million yuan, and 2.4% revenue growth in Q1 2026.
• National localization: the MIIT bioreactor initiative pairs Tofflon with Jiangnan University and CAS Shanghai Microsystems to develop domestic in-situ PAT sensors and mass-transfer components.

04EU#

The EU leads on in-line Raman PAT and the Quality-by-Design standards that frame its adoption.

raman pat leadership, qbd standards, process spectroscopy#

• Sartorius: in-line Raman PAT and bioprocess analytics for upstream feedback control of glucose and lactate and for downstream UF/DF endpoint determination.
• Mettler-Toledo: ReactRaman and ReactIR process analytics for in-line reaction and bioprocess monitoring with chemometric modeling.
• QbD and PAT framing: continuous Raman aligns with ICH Quality-by-Design and real-time quality assurance, which agencies encourage as modern manufacturing practice.

05Leading companies and research institutes#

06Tech stack and innovations#

The stack layers in-line spectroscopy, continuous purification and high-resolution analytics.

1. In-line Raman and spectroscopy (Raman Spectroscopy):
   • single-use Raman probes monitor glucose, lactate and titer in real time.
   • continuous Raman feedback can raise mAb titer about 10% and cut glycation up to 60% versus intermittent sampling.
2. Continuous multi-column chromatography (Periodic Counter-Current):
   • Cytiva’s AKTA pcc runs steady-state PCC across columns, using about 40% less buffer than batch.
   • UNICORN dimensionless scaling translates methods from 1 to 100 mL/min without re-optimization.
3. High-resolution mass spectrometry (Orbitrap MS):
   • Thermo Fisher’s Orbitrap Excedion adds enhanced dynamic range, detecting 3–5x more compounds.
   • BioPharma Finder 5.5 accelerates top-down protein characterization.

07Value chains and production pipelines#

Industrial pipeline of real-time release on a continuous train (ICH Q8/Q10)#

┌───────────────────────────┐      ┌───────────────────────────┐
│ 1. In-line sampling       │ ───> │ 2. Spectral preprocessing │
└───────────────────────────┘      └───────────────────────────┘
                                                 │
                                                 ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 4. Feedback control       │ <─── │ 3. CQA prediction         │
└───────────────────────────┘      └───────────────────────────┘
              │
              ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 5. QC analytics           │ ───> │ 6. Real-time release      │
└───────────────────────────┘      └───────────────────────────┘

Stage 1: In-line sampling

Single-use Raman, NIR and UV probes draw continuous spectra directly from the bioreactor and purification streams.

Stage 2: Spectral preprocessing

Chemometric baseline correction and noise reduction clean the raw signals for modeling.

Stage 3: CQA prediction

Multivariate models convert the spectra into critical quality attributes such as titer, glycation and aggregate levels.

Stage 4: Feedback control

Automated feed and column adjustments hold the predicted CQAs within their design ranges.

Stage 5: QC analytics

Liquid chromatography, high-resolution mass spectrometry and capillary electrophoresis confirm identity, purity and impurities.

Stage 6: Real-time release

Real-time release testing dispositions the batch under 21 CFR Part 11 data-integrity controls.